Regeneron says its Covid-19 antibody cocktail helps prevent symptomatic Covid-19

New Phase 3 trial data finds a single shot of Regeneron's Covid-19 antibody cocktail was able to prevent symptomatic Covid-19 among people exposed to the vir...

Posted: Apr 12, 2021 10:23 AM

New Phase 3 trial data finds a single shot of Regeneron's Covid-19 antibody cocktail was able to prevent symptomatic Covid-19 among people exposed to the virus, the company said Monday.

Regeneron said it will seek expansion of the emergency use authorization for the drug, which is currently available in the United States to treat mild-to-moderate Covid-19 in people already infected with the coronavirus.

In the new trial, the drug, named REGEN-COV, reduced risk of symptomatic infections by 81%, the company said Monday in a news release. The trial studied Regeneron's combination of casirivimab with imdevimab in 1,505 people who had not been infected with coronavirus but lived in the same household as someone who tested positive in the four days before. Each participant received one dose of the drug or a placebo, which does nothing, administered as an injection through the skin.

After 29 days, 11 people who received a single 1,200 mg dose of the treatment developed symptomatic Covid-19; 59 people who received a placebo developed symptomatic Covid-19. The drug provided 72% protection against symptomatic infections in the first week and 93% protection in subsequent weeks, Regeneron said. The data has not yet been peer reviewed or published.

Those who received the antibody cocktail and experienced a symptomatic infection resolved their symptoms in one week, the company said, compared to three weeks among those who received a placebo.

"Despite standard precautions to reduce transmission, nearly 10% of unvaccinated individuals living with an infected person developed symptomatic infections if they did not receive REGEN-COV," Dr. Myron Cohen, who leads the monoclonal antibody efforts for the COVID Prevention Network and is the director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, said in a statement. "If authorized, convenient subcutaneous administration of REGEN-COV could help control outbreaks in high-risk settings where individuals have not yet been vaccinated, including individual households and group living settings."

Adverse events occurred in 20% of patients who received the antibody drug and 29% of those who received a placebo, Regeneron said. None of the participants who received the drug were hospitalized or went to the ER because of Covid-19 over the course of 29 days; four in the placebo group did so. None of the four deaths in the trial -- two among those who received the drug and two who received a placebo -- were due to Covid-19 or the drug.

Regeneron said it will request an expansion of its US Food and Drug Administration emergency use authorization to include Covid-19 prevention and as a subcutaneous shot. The drug is currently authorized to be administered as an IV, which takes longer and may be part of the reason why uptake of the treatment has been limited.

The company also announced Monday that a second Phase 3 trial studied an injection of its antibody cocktail in 204 asymptomatic people recently infected with the coronavirus. A single shot reduced the risk of progressing to symptomatic Covid-19 by 31% overall. After the third day, risk was reduced by 76%. Participants received the treatment or a placebo, and the trial showed that the duration of symptoms was shortened and viral levels were reduced in those who received the antibody cocktail.

Eli Lilly and Company previously announced its monoclonal antibody therapy, bamlanivimab, helped prevent symptomatic Covid-19 infection among nursing home residents and staff. However, the US government said last month it will no longer distribute bamlanivimab for use on its own because of a sustained increase in coronavirus variants in the United States. Bamlanivimab can still be used with etesevimab, another monoclonal antibody treatment developed by Eli Lilly; in combination, the two Eli Lilly treatments seem to work against coronavirus variants.

So far, Regeneron's cocktail has been shown to be effective against coronavirus variants of concerns.

Oregon Coronavirus Cases

Data is updated nightly.

Cases: 313161

Reported Deaths: 3594
CountyCasesDeaths
Multnomah51245642
Washington34995276
Marion32577393
Clackamas26570271
Lane23989246
Jackson20977257
Deschutes16623102
Umatilla12602125
Douglas10712188
Linn1046886
Josephine8659165
Yamhill744999
Klamath643491
Polk623570
Malheur479467
Benton461927
Coos412069
Columbia324237
Jefferson313746
Lincoln276330
Union272737
Wasco239039
Crook212338
Clatsop211725
Tillamook181523
Baker174421
Morrow167921
Curry166817
Hood River163035
Harney78916
Grant7558
Lake6768
Wallowa50811
Gilliam1374
Sherman1283
Wheeler651
Unassigned00

California Coronavirus Cases

Data is updated nightly.

Cases: 4644566

Reported Deaths: 68019
CountyCasesDeaths
Los Angeles144512125852
Riverside3579884804
San Diego3495814009
San Bernardino3472035506
Orange3146225354
Sacramento1503072089
Santa Clara1405641841
Fresno1358611888
Kern1358421515
Alameda1162141329
Ventura976901120
San Joaquin973871615
Contra Costa95727924
Stanislaus806991234
Tulare72969896
San Mateo52239607
San Francisco51907605
Monterey49465565
Solano44151312
Santa Barbara43112500
Sonoma39441378
Merced39370535
Placer36487364
Imperial34261755
Kings30124284
San Luis Obispo28300313
Madera21707258
Butte21307230
Shasta20683276
Santa Cruz20151211
Yolo19143239
Marin17106242
El Dorado16004127
Sutter13094153
Napa1226895
Yuba926061
Nevada847685
Humboldt829587
Tehama823784
San Benito709067
Mendocino685575
Lassen637627
Tuolumne615393
Lake603687
Amador492259
Glenn398030
Siskiyou389541
Calaveras342266
Del Norte336034
Colusa290918
Inyo166539
Mono14935
Plumas12406
Mariposa99712
Trinity72010
Modoc6278
Sierra1980
Unassigned1650
Alpine1000
Out of CA00
Medford
Clear
56° wxIcon
Hi: 88° Lo: 46°
Feels Like: 56°
Brookings
Partly Cloudy
70° wxIcon
Hi: 84° Lo: 56°
Feels Like: 70°
Crater Lake
Clear
56° wxIcon
Hi: 69° Lo: 35°
Feels Like: 56°
Grants Pass
Partly Cloudy
56° wxIcon
Hi: 91° Lo: 46°
Feels Like: 56°
Klamath Falls
Clear
53° wxIcon
Hi: 78° Lo: 41°
Feels Like: 53°
Warmer temperatures with haze returning
KDRV Radar
KDRV Fire Danger
KDRV Weather Cam

Community Events